Skip to main content

Clinical Trials Using Venetoclax

Review the clinical trials studying venetoclax on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 101-125 of 156

Venetoclax, Lenalidomide, and Rituximab in Treating Patients with Mantle Cell Lymphoma
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Quizartinib, Decitabine, and Venetoclax in Treating Patients with Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients with Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Venetoclax with Combination Chemotherapy in Treating Patients with Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Nadunolimab and Azacitidine With or Without Venetoclax for the Treatment of Patients with Myelodysplastic Syndrome or Relapsed or Refractory Acute Myelogenous Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
ONC201 Alone or in Combination with Venetoclax in Treating Patients with Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Bomedemstat in Combination with Venetoclax for The Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Adult Patients, The VenBom Study
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Eltanexor and Venetoclax for the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
Status: Active
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
Venetoclax in Combination with ASTX727 for the Treatment of Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Q702 with Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Loncastuximab Tesirine and Venetoclax for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Ziftomenib, Venetoclax, and Azacitidine for the Treatment of Pediatric Patients with Relapsed and Refractory Acute Leukemias
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Venetoclax and Tocilizumab for the Treatment of Patients with Relapsed or Refractory t(11;14) Multiple Myeloma
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Venetoclax Combined with Intensive Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia or Intermediate and Higher Risk Myelodysplastic Syndrome
Status: Active
Location: Montefiore Medical Center-Weiler Hospital, Bronx, New York
8-Chloroadenosine in Combination with Decitabine and Venetoclax for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Iadademstat in Combination with Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Ziftomenib with Venetoclax and Gemtuzumab Ozogamicin for the Treatment of Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia or Mixed Phenotype Acute Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Ruxolitinib in Combination with Venetoclax with and without Azacitidine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: 3 locations
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Decitabine Alone or in Combination with Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon